5 Matching Annotations
  1. Feb 2026
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12869162/
  3. Feb 2025
  4. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11848832/
  5. Dec 2024
  6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11647204/
  7. Jan 2024
  8. www.sciencedirect.com www.sciencedirect.com
    A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S0092867423013223
  9. Nov 2022
  10. www.cell.com www.cell.com
    Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    cell.com/cancer-cell/fulltext/S1535-6108(22)00549-9